Association of Fusobacterium nucleatum with colorectal cancer molecular subtypes and its outcome: a systematic review.

Gut microbiome (Cambridge, England) Pub Date : 2025-04-08 eCollection Date: 2025-01-01 DOI:10.1017/gmb.2025.3

Luana Greco, Federica Rubbino, Clarissa Ferrari, Michela Cameletti, Fabio Grizzi, Fabrizio Bonelli, Alberto Malesci, Massimiliano Mazzone, Luigi Ricciardiello, Luigi Laghi

{"title":"Association of Fusobacterium nucleatum with colorectal cancer molecular subtypes and its outcome: a systematic review.","authors":"Luana Greco, Federica Rubbino, Clarissa Ferrari, Michela Cameletti, Fabio Grizzi, Fabrizio Bonelli, Alberto Malesci, Massimiliano Mazzone, Luigi Ricciardiello, Luigi Laghi","doi":"10.1017/gmb.2025.3","DOIUrl":null,"url":null,"abstract":"Colorectal cancer (CRC) represents a relevant public health problem, with high incidence and mortality in Western countries. CRC can occur as sporadic (65%-75%), common familial (25%), or as a consequence of an inherited predisposition (up to 10%). While unravelling its genetic basis has been a long trip leading to relevant clinical implementation over more than 30 years, other contributing factors remain to be clarified. Among these, micro-organisms have emerged as critical players in the development and progression of the disease, as well as for CRC treatment response. Fusobacterium nucleatum (Fn) has been associated with CRC development in both pre-clinical models and clinical settings. Fusobacteria are core members of the human oral microbiome, while being less prevalent in the healthy gut, prompting questions about their localization in CRC and its precursor lesions. This review aims to critically discuss the evidence connecting Fn with CRC pathogenesis, its molecular subtypes and clinical outcomes.","PeriodicalId":73187,"journal":{"name":"Gut microbiome (Cambridge, England)","volume":"6 ","pages":"e5"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12035788/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gut microbiome (Cambridge, England)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1017/gmb.2025.3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Colorectal cancer (CRC) represents a relevant public health problem, with high incidence and mortality in Western countries. CRC can occur as sporadic (65%-75%), common familial (25%), or as a consequence of an inherited predisposition (up to 10%). While unravelling its genetic basis has been a long trip leading to relevant clinical implementation over more than 30 years, other contributing factors remain to be clarified. Among these, micro-organisms have emerged as critical players in the development and progression of the disease, as well as for CRC treatment response. Fusobacterium nucleatum (Fn) has been associated with CRC development in both pre-clinical models and clinical settings. Fusobacteria are core members of the human oral microbiome, while being less prevalent in the healthy gut, prompting questions about their localization in CRC and its precursor lesions. This review aims to critically discuss the evidence connecting Fn with CRC pathogenesis, its molecular subtypes and clinical outcomes.

查看原文本刊更多论文

核梭杆菌与结直肠癌分子亚型的关联及其结果：一项系统综述。

结直肠癌（CRC）是一个相关的公共卫生问题，在西方国家发病率和死亡率都很高。结直肠癌可以是散发性的（65%-75%），常见的家族性的（25%），或者是遗传易感性的结果（高达10%）。尽管揭示其遗传基础是一个漫长的旅程，导致相关的临床实施超过30年，但其他影响因素仍有待澄清。其中，微生物在疾病的发展和进展以及CRC治疗反应中发挥了关键作用。在临床前模型和临床环境中，核梭杆菌（Fn）都与结直肠癌的发展有关。梭杆菌是人类口腔微生物组的核心成员，但在健康肠道中不太普遍，这引发了关于它们在结直肠癌及其前体病变中的定位的问题。本综述旨在批判性地讨论Fn与结直肠癌发病机制、其分子亚型和临床结果的证据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Gut microbiome (Cambridge, England)

自引率

0.00%

发文量